June 2026 Research Update

This month, the clearest progress was not a new treatment, but practical work to make newborn screening for Krabbe disease more reliable and easier to act on. One set of work showed that proficiency testing materials can help many labs produce consistent results for Krabbe and other similar conditions. Another study showed that even when the test result is clear, communication and coordination challenges can still slow down what happens next. [1] [2]

A laboratory program expanded its dried blood spot proficiency testing materials to include Krabbe disease, so screening laboratories can regularly check that their testing methods are performing as expected. In program deployment, 71 laboratories reported results and 98% were acceptable or correct, which supports the idea that this approach can scale across many sites and methods. The study also noted some technical issues to watch for, such as ion suppression in certain mass spectrometry approaches when enzyme enrichment is high. [1]

Separately, interviews with 25 outpatient pediatric clinicians highlighted that families may receive early information from clinicians who feel underprepared for Krabbe-specific questions. Common barriers included limited knowledge about Krabbe disease, lack of time during visits, and difficulty accessing specialists quickly, while suggested solutions included brief fact sheets or scripts and education provided alongside the newborn screening notification. This helps explain why follow-up after a positive screen can feel uneven depending on where a family receives care. [2]

For patients and caregivers, these studies mainly speak to what can happen around the first step of the Krabbe journey: a newborn screening result and the days that follow. The proficiency testing work may matter now at a system level because it supports more consistent screening performance across many laboratories, but it does not by itself change what an individual baby's result means. The communication study does not test medical outcomes, but it helps clarify why early conversations can vary and why better coordination and reliable, shared information resources are being proposed; it also remains uncertain which specific communication changes will measurably improve the family experience or speed of follow-up. [1] [2]

This month included early research aimed at understanding Krabbe biology and testing ideas in the lab, alongside a rare individual medical story that broadens what clinicians may look for. The lab study strengthens the set of tools researchers can use to test potential therapies by showing a human cell model that behaves in Krabbe-like ways and responds to a specific compound. The case report adds a reminder that Krabbe can appear in complex medical situations, including with other conditions, and may include symptoms outside the most familiar neurologic ones. [3] [4]

In a laboratory study, researchers used CRISPR to create a GALC knockout human oligodendrocyte cell line, which is meant to model Krabbe disease in the cells involved in myelin. These cells showed psychosine buildup and changes seen under muscle-strength microscopes (electron microscopy), including more autophagy-related structures and lower glycogen. When the cells were treated with BMN-S202 (a substrate reduction approach tested in the lab), psychosine levels dropped back to the levels seen in normal cells. [3]

A single case report described the first documented co-occurrence of Turner syndrome (45,X) and Krabbe disease in a child, confirmed by genetic testing and low GALC enzyme activity. The report noted secondary adrenal insufficiency (low cortisol due to reduced signaling from the brain) during the course of illness and discussed it as a possible unusual presentation, though the link to Krabbe remains uncertain. The child also received recombinant human growth hormone for short stature related to Turner syndrome, and the report described improved growth with no drug-related adverse events. [4]

For families, the laboratory findings are early-stage and mainly matter for future research, because results in cells do not predict how a treatment will work in people. What became clearer is that researchers now have a human oligodendrocyte model that captures a key Krabbe feature (psychosine buildup) and can show whether a candidate compound changes that signal in the lab. The case report is not something most families should expect to match, but it helps clarify the range of medical issues that can occur in an individual child and raises a research question about whether hormone-related problems could sometimes appear in Krabbe; that question remains open because it was based on one patient. [3] [4]